Cost-effectiveness of Brentuximab Vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China

Journal of Medical Economics ◽

10.1080/13696998.2021.2020567 ◽

2021 ◽

pp. 1-27

Author(s):

Jia Liu ◽

Lei Zheng ◽

Ling-Hsiang Chuang

Keyword(s):

Cost Effectiveness ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Large Cell Lymphoma

Download Full-text

PCN56 Brentuximab Vedotin PLUS CHP in Frontline Systemic Anaplastic Large Cell Lymphoma (SALCL): Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Retreatment with Brentuximab Vedotin

Value in Health ◽

10.1016/j.jval.2020.08.193 ◽

2020 ◽

Vol 23 ◽

pp. S431

Author(s):

H. Cranmer ◽

D. Trueman ◽

F. Woodcock ◽

E. Evers ◽

T. Podkonjak

Keyword(s):

Cost Effectiveness ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Large Cell Lymphoma

Download Full-text

PCN39 Cost-Effectiveness of Brentuximab Vedotin for Relapsed or Refractory Systemic Anaplastic Large-CELL Lymphoma in China

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.089 ◽

2020 ◽

Vol 22 ◽

pp. S12

Author(s):

L.H. Chuang ◽

W. Xu ◽

L. Zheng ◽

W. Sun ◽

W. Zhang

Keyword(s):

Cost Effectiveness ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Large Cell Lymphoma

Download Full-text

Cost-Effectiveness of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma in Taiwan

Value in Health ◽

10.1016/j.jval.2016.08.705 ◽

2016 ◽

Vol 19 (7) ◽

pp. A811

Author(s):

D Zou ◽

R Kendall ◽

Q Lin ◽

Y Huang ◽

J Tieng ◽

...

Keyword(s):

Cost Effectiveness ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Large Cell Lymphoma

Download Full-text

Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma

10.1055/s-0040-1701850 ◽

2020 ◽

Author(s):

Y Koga ◽

M Sekimizu ◽

A Iguchi ◽

A Kada ◽

A Saito ◽

...

Keyword(s):

Phase I ◽

Anaplastic Large Cell Lymphoma ◽

Phase I Study ◽

Hodgkin’S Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Japanese Children ◽

Large Cell Lymphoma

Download Full-text

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2015.03.011 ◽

2015 ◽

Vol 95 (3) ◽

pp. 359-369 ◽

Author(s):

P.L. Zinzani ◽

S. Sasse ◽

J. Radford ◽

O. Shonukan ◽

V. Bonthapally

Keyword(s):

Hodgkin Lymphoma ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Program Review ◽

Review Of The Literature ◽

Large Cell Lymphoma ◽

Refractory Hodgkin Lymphoma

Download Full-text

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol

10.1186/s12885-018-4042-1 ◽

2018 ◽

Vol 18 (1) ◽

Author(s):

Masahiro Sekimizu ◽

Akihiro Iguchi ◽

Tetsuya Mori ◽

Yuhki Koga ◽

Akiko Kada ◽

...

Keyword(s):

Clinical Study ◽

Phase I ◽

Study Protocol ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Large Cell Lymphoma ◽

Design And Methods

Download Full-text

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Expert Review of Hematology ◽

10.1080/17474086.2021.1942831 ◽

2021 ◽

Author(s):

Yuqin Song ◽

Ye Guo ◽

Huiqiang Huang ◽

Wei Li ◽

Xiaoyan Ke ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Chinese Patients ◽

Classical Hodgkin Lymphoma ◽

Large Cell Lymphoma

Download Full-text

Faculty Opinions recommendation of Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734167581.793581834 ◽

2021 ◽

Author(s):

David Teachey

Keyword(s):

Anaplastic Large Cell Lymphoma ◽

Hodgkin’S Lymphoma ◽

Cell Lymphoma ◽

Phase 1 ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Open Label Phase ◽

Large Cell Lymphoma

Download Full-text

Case 19. Successful treatment of primary cutaneous anaplastic large cell lymphoma on the penile shaft with brentuximab vedotin and allogenic stem cell transplant

Cutaneous Lymphomas ◽

10.1007/978-3-030-59129-8_19 ◽

2021 ◽

pp. 42-43

Author(s):

J. Yoo ◽

A. Stevens ◽

S. Chaganti ◽

J. Scarisbrick

Keyword(s):

Stem Cell ◽

Successful Treatment ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Cell Transplant ◽

Penile Shaft ◽

Allogenic Stem Cell Transplant ◽

Large Cell Lymphoma

Download Full-text

Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study

Leukemia & Lymphoma ◽

10.1080/10428194.2019.1654100 ◽

2019 ◽

Vol 61 (1) ◽

pp. 176-180 ◽

Author(s):

Noriko Fukuhara ◽

Go Yamamoto ◽

Hideki Tsujimura ◽

Takaaki Chou ◽

Hirohiko Shibayama ◽

...

Keyword(s):

Retrospective Study ◽

Hodgkin Lymphoma ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Classical Hodgkin Lymphoma ◽

Large Cell Lymphoma

Download Full-text